Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Aged
Antimetabolites, Antineoplastic
/ therapeutic use
Azacitidine
/ therapeutic use
Blast Crisis
/ diagnosis
Female
Humans
Hydroxyurea
/ therapeutic use
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
/ diagnosis
Male
Melphalan
/ therapeutic use
Middle Aged
Mutation
Myeloproliferative Disorders
/ diagnosis
Pipobroman
/ therapeutic use
Polycythemia Vera
/ diagnosis
Primary Myelofibrosis
/ diagnosis
Prognosis
Remission Induction
Retrospective Studies
Thrombocythemia, Essential
/ diagnosis
Treatment Outcome
accelerated phase
azacytidine
blastic phase
myeloproliferative neoplasms
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
20
03
2019
revised:
29
04
2019
accepted:
29
04
2019
pubmed:
6
5
2019
medline:
10
9
2019
entrez:
4
5
2019
Statut:
ppublish
Résumé
There have been some reports on a possible role of azacytidine (AZA) in the treatment of accelerated/blastic phase evolved from Philadelphia-negative myeloproliferative neoplasms (MPN-AP/BP), but results are conflicting. In this study, we analyzed a cohort of 39 patients with MPN-AP/BP treated frontline with AZA at the standard dosage (75 mg/m
Substances chimiques
Antimetabolites, Antineoplastic
0
Pipobroman
6Q99RDT97R
Azacitidine
M801H13NRU
Melphalan
Q41OR9510P
Hydroxyurea
X6Q56QN5QC
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
291-295Informations de copyright
© 2019 John Wiley & Sons, Ltd.
Références
Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol. 1991;85(3):124-127.
Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105(3):973-977.
Mollard LM, Chauveau A, Boyer-Perrard F, et al. Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase. Leuk Lymphoma. 2018;59(12):2812-2820.
Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105(7):2664-2670.
Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429-2440.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
Maurillo L, Venditti A, Spagnoli A, et al. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian compassionate program. Cancer. 2012;118(4):1014-1022.
Thepot S, Itzykon R, Seegers V, et al. Treatment of progression in Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood. 2010;116(19):3735-3742.
Andriani A, Montanaro M, Voso MT, et al. Azacytidine for the treatment of Myeloproliferative Neoplasm in blastic phase: a retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. Leuk Res. 2015;39(8):801-804.
Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31(6):737-740.
Mascarenhas J, Heaney ML, Najfeld V, et al. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leuk Res. 2012;36(12):1500-1504.
Drummond MW, Harrison CN, Vicente SM, et al. A phase Ib study to assess the safety and tolerability of Ruxolitinib in combination with Azacitidine in patients with advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPN. Blood. 2017;130:1649.
Rampal RK, Mascarenhas J, Kosiorek HE, et al. Efficacy of combined ruxolitinib and decitabine in patients with accelerated and blast-phase myeloproliferative neoplasms: results of a phase II study (MPN-RC 109 trial). Blood. 2018;132.
Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291-299.
Maurillo L, Buccisano F, Spagnoli A, et al. Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia. Ann Hematol. 2018;97(10):1767-1774.
Girmenia C, Candoni A, Delia M, et al. Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. Blood Rev. 2018 Oct 28. pii: S0268-960X(18)30069-9;34:16-25. https://doi.org/10.1016/j.blre.2018.10.002
Di Nardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216-228. https://doi.org/10.1016/S1470-2045(18)30010-X